EUCTR2007-005685-12-AT
Active, not recruiting
Not Applicable
The influence of hormone replacement therapy on the cerebral serotonin-1A receptor distribution and mood in postmenopausal women - Hormone replacement therapy and serotonin-1A receptors
niversitätsklinik für Psychiatrie und Psychotherapie, Klin. Abteilung f. Biologische Psychiatrie0 sitesJuly 7, 2008
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Healthy postmenopausal women receiving standard hormone replacement therapy are measured using positron emission tomography to investigate the effects of hormones on the cerebral serotonin-1A receptor.
- Sponsor
- niversitätsklinik für Psychiatrie und Psychotherapie, Klin. Abteilung f. Biologische Psychiatrie
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Postmenopausal females in good condition (over 14 months of amenorrhoea)
- •Age 50 \- 65 years
- •Uni\- or Multipara
- •Signed informed consent form
- •Consent not to participate in PET or SPECT studies with an added equivalence dose of over 15 mSv within 10 years following the final assessment of the participant in this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
Exclusion Criteria
- •Steroid hormone treatment within 6 months prior to the inclusion
- •Current substance abuse
- •History of any malign illness
- •Any implant or stainless steel graft
- •Concomitant neurological illness
- •Concomitant psychiatric disorder except anxiety disorders or depression
- •Treatment with a psychotropic agent targeting serotonin\-1A and serotonin\-2A receptors or the serotonin transporter such as buspirone, pindolol or SSRIs.
- •Clinically relevant abnormalities in the general physical examination and the routine laboratory screening
- •Concomitant major illness, especially: liver disease, disorder of the endocrine system, osteoporosis (when treated with vitamine D), any clinically relevant vascular or heart diseases
- •One of the following gynaecological diseases: ovariectomy, hysterectomy, endometriosis, myomatosis, cervical smear test: PAP \> II
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Effect of hormone replacement therapy versus risedronate on fracture recurrence in postmenopausal women with hip fractureEndocrine, nutritional and metabolic diseaseKCT0005513Samsung Medical Center300
Completed
Not Applicable
The effect of hormonal replacement therapy on menopausal complaints related to biochemical changes in surgically and naturally postmenopausal women. A prospective observational comparative study.NL-OMON30054Antoni van Leeuwenhoek Ziekenhuis280
Completed
Not Applicable
The Effect of Low Dose Hormone Replacement Therapy or Raloxifene on Bone and Lipid Metabolism in Hemodialysis PatientsPostmenopausal osteopenia in hemodialysis patientsJPRN-C000000390Department of Nephrology, Osaka University School of Medicine39
Completed
Phase 3
Comparative effects of 2 types of hormone replacement therapy on climacteric symptomsmenopause.Menopausal and female climacteric statesIRCT138809032766N1Tarbiat Maodares University150
Completed
Phase 2
Effect of hormonal therapy versus no treatment on testicular histopathology and fertility in patients with non-obstructive azoospermianon-obstructive azoospermia.Male infertilityIRCT201612069014N137Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences28